Innate Pharma (IPHA) Appoints Jonathan Dickinson as CEO and Board Chair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
October 14, 2024 1:01 AM EDTJonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma Current interim CEO and co-founder Hervé Brailly will support the transition
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that its supervisory Board has appointed Jonathan Dickinson as the Companys new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of... More
